A phase III trial of Toca 511 + Toca FC in patients with newly diagnosed HGG and other solid tumors:Toca 5
Phase of Trial: Phase III
Latest Information Update: 08 Nov 2017
At a glance
- Drugs Vocimagene amiretrorepvec-flucytosine gene therapy (Primary)
- Indications Glioma; Solid tumours
- Focus Registrational; Therapeutic Use
- Sponsors Tocagen
- 08 Nov 2017 According to a Tocagen media release, the company has modified two-step trial design (Phase 2 followed by a Phase 3) into this seamless, pivotal trial.
- 11 Mar 2016 New trial record
- 08 Mar 2016 This trial is expected to begin in 2016, according to a Tocagen media release.